ÇѸ²´ëÇб³ Àǰú´ëÇÐ Ç÷¾×Á¾¾ç³»°ú

2010³â09¿ù10ÀÏ Friday
¿ÃÇØ ½ÃÀÛÇÑÁö 253Àϰ
(69.32 percent Áö³²)






¢Ã Ç÷¾×Á¾¾ç³»°ú ¼Ò°³
¢Ã Ç÷¾×Á¾¾çÇÐ ÅëÇÕ°­ÀÇ
¢Ã °Ô½ÃÆÇ
¢Ã ±³À° ÀÚ·á
¢Ã ¿¬±¸ ÀÚ·á
¢Ã Áø·á ÀÚ·á
¢Ã ¸µÅ©



[Á¢¼ÓÅë°è]
¿À´Ã¹æ¹®ÀÚ: 127
¾îÁ¦¹æ¹®ÀÚ: 169
Àüü¹æ¹®ÀÚ: 181,138
ÇöÀçÁ¢¼ÓÀÚ: 4
Ãִ뵿½ÃÁ¢¼ÓÀÚ: 90
ÃÖ´ë¹æ¹®ÀÚ: 1,090


   °øÁö»çÇ× ¹× ÀÚÀ¯°Ô½ÃÆÇ

more  

[±èÁ¤ÇÑ] ±³¿øº° ´ã´çÁúȯ


[±èÁ¤ÇÑ] ±³¿øº° ¾÷¹«


[±èÁ¤ÇÑ] À̱ټ® ±³¼ö´Ô °¨»çÇÕ´Ï´Ù.


[¾ÈÁø¼®] IIP CRF ¿Ã·ÁÁÖ¼¼¿ä.


[Á¤ÁÖ¿µ] Çлý °­ÀÇ¿¡ ´ëÇÑ Àǰ߰ú Àü°øÀÇ Áöħ¼­ºÎºÐ


   ÅëÇÕ °­ÀÇ ¹× Ç÷¾×Á¾¾çÇÐ ±³À° °ü·Ã ÀÚ·á

more  

[¤µ¤Ó Ƽ·£µå] ½ÃƼ·£µå.Ä«¤¸¤Ó ³ë,ctct777.tk


[Á¤¹Ì¿µ] ·ê·¿°ÔÀÓ»çÀÌÆ®


[»ç¶û¿¹°¨] ¼ºÀε¿¿µ»ó´Ù¿î


[¸±°ÔÀÓ] ¿Â¶óÀÎÀÇ ¸ðµç ¸±°ÔÀÓ ÃÑÁýÇÕ »çÀÌÆ® http://m77.co2.in/


[¼ºÀϵ¿] Ȳ±Ý¼º°ÔÀÓ»çÀÌÆ®


   Ç÷¾×Á¾¾çÇÐ ¿¬±¸ ÀÚ·á

more  

[±èÁ¤ÇÑ] Alimta+Carbo as 2nd-line chemotherapy in NSCLC


[±ÇÁ¤Çý] fractionated docetaxel and cisplatin in NSCLC(°¡Á¦)_CRF


[±ÇÁ¤Çý] fractionated docetaxel and cisplatin in NSCLC(°¡Á¦)_Àӻ󿬱¸½Åû¼­


[±ÇÁ¤Çý] fractionated docetaxel and cisplatin in NSCLC(°¡Á¦)_protocol and ÇÇÇèÀÚ µ¿ÀǼ­


[±ÇÁ¤Çý] °¢º´¿øÀÇ °ø½Ä ¿µ¹® Ç¥±âÀÔ´Ï´Ù.


   Ç÷¾×Á¾¾çÇÐ Áø·á ÀÚ·á

more  

[À̱ټ®] °ñ¼öÀ̽ÄÈÄ immunization


[À̱ټ®] Rituximab º¸Çè ±âÁØ 2004. 10. 1.ÀÏÀÚ


[À̱ټ®] ÀڱðæºÎ¾Ï¿¡ cisplatin-concurrent RT ¿ë¹ý ±Þ¿©¹üÀ§ Å뺸 ¾È³»


[À̱ټ®] irinotecan º¸Çè ±âÁØ


[À̱ټ®] interferon alpha-2a, 2b º¸Çè ±âÁØ




Copyright ¨Ï 2004 Hematology and Medical Oncology, Hallym University. All rights reserved.


ÿ